Tuesday, August 13, 2019
Posted by: Natasha Azar
OUP participated in the $60M Series B financing of Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. The round was co-led by Perceptive Advisors and RTW Investment, with participation from PBM Capital and OUP.
Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. The proceeds of the financing will be used towards Phase 2 trials for ulcerative colitis and Crohn's Disease. Read more here.